40 citations
,
April 2018 in “Endocrine” This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.
11 citations
,
April 2018 in “Journal of Dermatology” In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.
13 citations
,
December 2017 in “CNS Neuroscience & Therapeutics” In this study, finasteride was found to inhibit the dopaminergic system and reduce open-field behaviors in adolescent male rats by decreasing dopamine levels and related proteins.
27 citations
,
May 2015 in “Neuropharmacology” This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.
7 citations
,
October 2009 in “Journal of the American Geriatrics Society” This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.
38 citations
,
January 2005 in “PubMed” This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.
187 citations
,
January 1994 in “The New England Journal of Medicine” Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.